Ironwood Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 2006
Revenue	442.74	410.6	413.75	389.52	428.41	Upgrade
Revenue Growth (YoY)	7.83%	-0.76%	6.22%	-9.08%	23.59%	Upgrade
Cost of Revenue	0	0	0	3.14	23.88	Upgrade
Gross Profit	442.74	410.6	413.75	386.39	404.54	Upgrade
Selling, General & Admin	158.31	115.99	111.13	140	172.45	Upgrade
Research & Development	116.09	44.27	70.41	88.06	115.04	Upgrade
Other Operating Expenses	1,114	0	-0.04	15.38	-3.08	Upgrade
Operating Expenses	1,388	160.26	181.49	243.45	284.42	Upgrade
Operating Income	-945.43	250.34	232.26	142.94	120.12	Upgrade
Interest Expense / Income	21.63	7.6	31.15	29.48	36.6	Upgrade
Other Expense / Income	-48.31	-9.68	0.45	4.6	62.02	Upgrade
Pretax Income	-918.75	252.42	200.66	108.86	21.51	Upgrade
Income Tax	83.49	77.36	-327.79	2.69	0	Upgrade
Net Income	-1,002.24	175.07	528.45	106.18	21.51	Upgrade
Net Income Growth	-	-66.87%	397.71%	393.73%	-	Upgrade
Shares Outstanding (Basic)	155	154	162	159	156	Upgrade
Shares Outstanding (Diluted)	155	186	164	161	156	Upgrade
Shares Change	-16.57%	13.32%	2.34%	2.97%	2.22%	Upgrade
EPS (Basic)	-6.45	1.13	3.26	0.67	0.14	Upgrade
EPS (Diluted)	-6.45	0.96	3.21	0.66	0.14	Upgrade
EPS Growth	-	-70.09%	386.36%	371.43%	-	Upgrade
Free Cash Flow	183.15	273.63	261.63	166.99	3.8	Upgrade
Free Cash Flow Per Share	1.18	1.77	1.61	1.05	0.02	Upgrade
Gross Margin	100.00%	100.00%	100.00%	99.19%	94.43%	Upgrade
Operating Margin	-213.54%	60.97%	56.13%	36.70%	28.04%	Upgrade
Profit Margin	-226.37%	42.64%	127.72%	27.26%	5.02%	Upgrade
Free Cash Flow Margin	41.37%	66.64%	63.23%	42.87%	0.89%	Upgrade
Effective Tax Rate	-	30.65%	-163.36%	2.47%	-	Upgrade
EBITDA	-895.55	261.44	233.33	141.9	63.69	Upgrade
EBITDA Margin	-202.28%	63.67%	56.39%	36.43%	14.87%	Upgrade
Depreciation & Amortization	1.58	1.42	1.52	3.56	5.58	Upgrade
EBIT	-897.12	260.02	231.81	138.34	58.11	Upgrade
EBIT Margin	-202.63%	63.33%	56.03%	35.51%	13.56%	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).